1 / 20

Kim Solez, M.D.

Landing on the Moon at Last! New Pathologic Landscapes In Renal Transplantation with Lymphocyte-depleting Anti-Rejection Protocols. Kim Solez, M.D. The Apollo moon landing of 1969 became the model for adventure and exploration for a generation.

zamir
Download Presentation

Kim Solez, M.D.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Landing on the Moon at Last!New Pathologic Landscapes In Renal Transplantation withLymphocyte-depleting Anti-Rejection Protocols. Kim Solez, M.D.

  2. The Apollo moon landing of 1969 became the model for adventure and exploration for a generation.

  3. A quarter century later in 1992 Cal Stiller called me about the first MMF biopsies:“Kim, Kim, It’s like landing on the moon! Like nothing you have ever seen before!” Calvin R. Stiller, M.D. Chair Canadian Medical Discoveries Fund Awarded the Order of Canada Established the Multi-Organ Transplant Service at UWO in London, Ontario

  4. Cal Stiller Directed Canadian Multicenter Trials of Cyclosporine Therapy in Renal Allografts in 1980s - A legendary figure in transplantationIn 1978, Dr. Cal Stiller, who was attending a transplant meeting in Rome, tried without success to meet the scientist who had discovered a promising new anti-rejection drug, to discuss testing it in London.It was raining as Stiller finally found a cab in St. Peter's Square. Nearby, standing in the downpour, was a very wet Swiss scientist, Jean F. Borel, discoverer of cyclosporine.They shared the taxi and when the trip was over, it was decided London would be the site of clinical trials of the new agent that was to save countless lives around the world.

  5. Virtual Pathology Slide • http://www.telepathology.dcu.ie/vps02.php3VPS Breast Needle Core Study (JMIR 2003) • http://www.medicine.uiowa.edu/pathology/uarep_histopathology/ Virtual slidebox of histopathology • http://alf3.urz.unibas.ch/patho/pub/2002-11.htmHuman Pathology -- Volume 34, No. 10 (October 2003) -- pages 968-974 Katharina Glatz-Krieger , Dieter Glatz , Michael J. Mihatsch Virtual Slide: high quality demand, physical limitations and affordability. http://vmic.unibas.ch

  6. The ScanScope SystemA Complete Virtual Microscopy System

  7. The First MMF Biopsies from the University of Wisconsin Cal Stiller was wrong at that moment in 1992. There was nothing unique about the morphologic changes seen under the influence of MMF. His impression otherwise was due to his unfamiliarity with kidney sections embedded in plastic as opposed to the usual paraffin embedding.

  8. Wrong at the time in 1992, but presaging events of the present. However in a more general sense his words presaged an inevitable outcome of the development of new anti-rejection agents:  Eventually there will be compounds or strategies used which will profoundly alter the pathologic landscape and the rules for diagnosis of rejection, and such a major morphologic development may usher in a new clinical era of anti-rejection therapy.

  9. So are we there yet? Have we landed on the moon? Recently several biopsies from lymphocyte depleting clinical trails have shown a picture of predominant infiltration by cells of macrophage monocyte lineage, behaving like rejection clinically but fulfilling none of the usual criteria for rejection which require lymphocytes in tubules and arteries. So perhaps indeed the rules are changing! And the situation now?

  10. For the details …. You must be patient!

  11. The fluidity of the pathological landscape in the transplanted kidney seems to have been consistently underestimated, the psychological "some things never change" mindset of human beings seems to promote the erroneous view that some changes in the kidney are unidirectional and permanent until the end of time. Much persuasive evidence argues against this. Assumptions

  12. Slides from Roz Mannon, Alan Kirk These pictures were taken by their pathologist, David Kleiner, on 15 Alemtuzumab patients. They received Alemtuzumab alone (n=6), with rapa (n=2), or Infliximab and rapa (n=4) or with DSG and rapa (n=3).

  13. Methods • All patients enrolled on Alemtuzumab (CAMPATH 1H) treatment • All biopsies taken through day 100 • BANFF 97 criteria used to grade rejections • Infiltrates immuno-phenotyped using antibodies against CD3, CD4, CD8, CD20, CD45, CD45RO, CD68, HLA-DR, perforin, granzyme B

  14. Results - Biopsies • 53 total biopsies (52 needle bx, 1 wedge) • Adequacy: 32 adequate, 13 subopt, 8 inadeq • Glomeruli: mean 15 (0-45) • Arteries: mean 2 (0-7)

  15. Clinical/Histological Rejection • 12/15 patients had an episode of increased Cr to at least 1.5x baseline in the first 100 days • Histologic correlation in 9 patients: • 3 Borderline • 1 Grade IA • 3 Grade IB • 1 Grade IIA • 1 Grade IIB

  16. Day 0 Day 21 Day 14 HLA-DR Immunostaining Progression

  17. Day 0 Day 14 Day 22 Day 21 Progression of CD68 Infiltration in Alemtuzumab Treated Recipients

  18. Focal Macrophage Infiltrate Corresponds to Focal HLA-DR Expression HLA-DR CD68

  19. Composite of Campath Rejection vs. Non-Depletional Rejection CD3 HLADR CD68 AR Alem

  20. Practical Implications for Classification ? Routine staining for CD68 Probably no formal change in classification until experience with this new type of rejection grows. Sharing of morphologic data as important as sharing of genomics data.

More Related